Clinical Trial Update: A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression [Phase 2]

View source ↗

Summary

This document reports a Phase 2 prospective, single-arm exploratory study evaluating the investigational drug IBI363 in patients with extensive-stage small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• IBI363

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: SCLC,Extensive Stage | Phase 2 | Status: NOT_YET_RECRUITING